Results 91 to 100 of about 2,835 (182)

State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review

Pharmaceuticals
Background/Objectives: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing inflammation and incomplete response to conventional therapies.
Yunseok Choi, Suhyun Lee, Hyeon Ji Kim, Taemin Park, Won Gun Kwack, Seungwon Yang, Eun Kyoung Chung   +6 more
doaj   +1 more source

Filgotinib in cutaneous lupus: is a negative positive? [PDF]

Rheumatology, 2021
Kathryn Connelly, Eric F Morand
openaire   +2 more sources

Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis

Indian Journal of Rheumatology
This review aims to provide a comprehensive analysis of filgotinib, a selective Janus kinase 1 (JAK1) inhibitor, and its potential applications in the treatment of rheumatoid arthritis (RA). It assesses filgotinib’s efficacy, safety, and role compared to
Krishna. S Upadhye, Paritosh Tayade, Hariom Patidar, Narendra Yadav   +3 more
doaj   +1 more source

Process for the preparation of Filgotinib maleate

The present invention relates to crystalline form of N-(5-{4-[(1,1-dioxidothiomorpholin-4-yl)methyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropane carboxamide, maleate of formula-1 referred to as Filgotinib maleate, which is represented by the ...
, MSN Laboratories Private Limited, R&D Center, Hyderabad, India, Srinivasan Thirumalai Rajan, KESHAVAREDDY, Navin Kumar Reddy, Dr. P. Raja Gopal, V.Dathatreya
core   +1 more source

Therapeutic drug monitoring with non-anti-TNF advanced therapies in inflammatory bowel disease: current and evolving paradigms

Frontiers in Gastroenterology
Inflammatory bowel diseases, encompassing Crohn’s disease and ulcerative colitis, are chronic inflammatory disorders of the gastrointestinal tract. The recent expansion in advanced therapy options has not dramatically altered the ceiling of treatment ...
Faris Chater, Thomas D. Butler, Thomas D. Butler, Jimmy K. Limdi, Jimmy K. Limdi   +4 more
doaj   +1 more source

Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinib

Background: Filgotinib, a Janus kinase 1-preferential inhibitor, is approved for the treatment of moderately to severely active ulcerative colitis (UC). Aim: To assess the effects of filgotinib on endo-histological outcomes and tissue RNA sequencing data
Bauer, Yasmina, Feagan, Brian G, Rogler, Gerhard, Randall, Matthew, Oortwijn, Alessandra, Magro, Fernando, Peyrin-Biroulet, Laurent, Cougnaud, Laure, Rudolph, Christine, Faes, Margaux, Reinisch, Walter   +10 more
core   +1 more source

Filgotinib [PDF]

, 2020
openaire   +1 more source

A case of rhupus treated with filgotinib: A promising therapeutic perspective

Rhupus syndrome: Rhupus syndrome, characterized by overlapping clinical features of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), presents significant therapeutic challenges due to its complex pathogenesis and limited treatment ...
Rella V., Paolo Cantatore F., Corrado A., Barile R., Rotondo C.   +4 more
core   +1 more source

Efficacy and tolerability of janus kinase inhibition strategies for moderate-to-severe Crohn's disease: A systematic review and bayesian network meta-analysis. [PDF]

Ther Adv Gastroenterol
Wazir HU, Mehta K, Shabbir MS, Islam MR, Maaz M, Muzaffar M, Ehsan N, Aliha S, Chauhan A, Khurram A, Saffouri G.   +10 more
europepmc   +1 more source

Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies. [PDF]

Rheumatol Ther
Burmester GR, Galloway J, Bevers K, Avouac J, Romero-Yuste S, Caporali RF, Betteridge N, Van der Donckt C, Debray TPA, Tandjaoui Bouzid O, Verschueren P.   +10 more
europepmc   +1 more source